Division of Hematology and Oncology;
Perlmutter Cancer Center;
New York University School of Medicine;
Immunotherapy; Pancreatic; cancer; Antiprogrammed; cell; death; protein-1; Anti-programmed; cell; death; protein-ligand1; Anti-cytotoxic; T; lymphocyte; antigen-4; Single; therapy; Combination; therapies; Radiation; therapy; GVAX; CRS-207; CD40; agonist;